• Annual Reports in Medicinal Chemistry (Paperback) 9780123964922
1 1
£79.49 GBP
£118.00 GBP £79.49 GBP
Sale Sold out
Free UK Shipping

Freshly Printed - allow 10 days lead

Annual Reports in Medicinal Chemistry

Timely and critical reviews of important topics in medicinal chemistry

John E. Macor (Series edited by)

9780123964922

Paperback, published 16 November 2012

472 pages
22.9 x 15.1 x 3 cm, 0.89 kg

This series is one of the very few annual publications which justify the title of an absolute must for the pharmacologist, chemist, or physician who is interested in the chemistry of drug development." --Enzymologia

Annual Reports in Medicinal Chemistry provides timely and critical reviews of important topics in medicinal chemistry together with an emphasis on emerging topics in the biological sciences, which are expected to provide the basis for entirely new future therapies.

Personal Essay

  1. Reflections on Medicinal Chemistry at Merck, West Point

    2. Paul S. Anderson

  2. My Path in Seeking New Medicines

    3. Peter R. Bernstein

  3. Tales of Drug Discovery

    4. M. Ross Johnson

    I. Central Nervous System Diseases

    Section Editor: Albert J. Robichaud; Sage Therapeutics, Inc. Cambridge, Massachusetts

  4. Recent Developments in Targeting Neuroinflammation in Disease

    5. Allen T. Hopper, Brian M. Campbell, Henry Kao, Sean A. Pintchovski and Roland G. W. Staal

  5. Secretase Inhibitors and Modulators as a Disease Modifying Approach Against Alzheimer’s Disease

    6. Harrie J. M. Gijsen and François P. Bischoff

  6. mGluR2 Activators and mGluR5 Blockers Advancing in the Clinic for Major CNS Disorders

    7. Sylvain Célanire, Guillaume Duvey, Sonia Poli and Jean-Philippe Rocher

  7. NMDA Antagonists of GluN2B Subtype and Modulators of GluN2A, GluN2C and GluN2D Subtypes – Recent Results and Developments

    8. Kamalesh B. Ruppa, Dalton King and Richard Olson

  8. Recent Advances in the Development of PET and SPECT Tracers for Brain Imaging

    9. Lei Zhang and Anabella Villalobos

    II. Cardiovascular and Metabolic Diseases

    Section Editor: Andy Stamford, Merck Research Laboratories, Kenilworth, New Jersey

  9. Case History: EliquisTM (Apixaban), a Potent and Selective Inhibitor of Coagulation Factor Xa for the Prevention and Treatment of Thrombotic Diseases

    10. Donald J. P. Pinto, Pancras C. Wong, Robert M. Knabb and Ruth R. R. Wexler

  10. AMPK Activation in Health and Disease

    11. Iyassu K. Sebhat and Robert W. Myers

  11. Type-2 Diabetes and Associated Co-Morbidities as an Inflammatory Syndrome

    12. Juan C. Jaen, Jay P. Powers and Tim Sullivan

  12. Beyond PPARs & Metformin: New Insulin Sensitizers for the Treatment of Type 2 Diabetes

    13. Philip A. Carpino and David Hepworth

    III. Inflammatory Pulmonary and Gastrointestinal Diseases

    Section Editor: David S. Weinstein, Bristol-Myers Squibb R&D, Princeton, New Jersey

  13. Recent Advances in the Discovery and Development of Sphingosine-1-Phosphate-1 Receptor Agonists

    14. Alaric J. Dyckman

  14. Bifunctional Compounds for the Treatment of COPD

    15. Gary Phillips and Michael Salmon

  15. Inflammatory Targets for the Treatment of Atherosclerosis

    16. Robert O. Hughes, Alessandra Bartolozzi and Hidenori Takahashi

    IV. Oncology

    Section Editor: Shelli R. McAlpine, School of Chemistry, University of New South Wales, Sydney, Australia

  16. Nanotechnology Therapeutics in Oncology – Recent Developments and Future Outlook

    17. Paul F. Richardson

  17. Small-Molecule Antagonists of Bcl-2 Family Proteins

    18. Sean P. Brown and Joshua P. Taygerly

  18. Notch Pathway Modulators as Anti-Cancer Chemotherapeutics

    19. Vibhavari Sail and M. Kyle Hadden

  19. Anaplastic Lymphoma Kinase (ALK) Inhibitors for the Treatment of ALK-Positive Cancers

    20. Kazutomo Kinoshita, Nobuhiro Oikawa and Takuo Tsukuda

    V. Infectious Diseases

    Section Editor: John Primeau, Westford, Massachusetts

  20. Recent Advances in the Discovery of Dengue Virus Inhibitors

    21. Jeremy Green, Upul Bandarage, Kate Luisi and Rene Rijnbrand

  21. Non Fluoro-Quinolone Based Inhibitors of Mycobacterial Type II Topoisomerase as Potential Therapeutic Agents for TB

    22. Pravin S. Shirude and Shahul Hameed

  22. HCV Inhibition Mediated through the Nonstructural Protein 5A (NS5A) Replication Complex

    23. Robert Hamatake, Andrew Maynard and Wieslaw M. Kazmierski

    VI. Topics in Biology

    Section Editor: John Lowe, JL3Pharma LLC, Stonington, Connecticut

  23. Antibody-Drug Conjugates for Targeted Cancer Therapy

    24. Victor S. Goldmacher, Thomas Chittenden, Ravi V. J. Chari, Yelena V. Kovtun and John M. Lambert

  24. 3D Cell Cultures: Mimicking in Vivo Tissues for Improved Predictability in Drug Discovery

    25. Indira Padmalayam and Mark J. Suto

  25. Virally Encoded G Protein-Coupled Receptors: Overlooked Therapeutic Opportunities?

    26. Nuska Tschammer

  26. Recent Advances in Wnt/b-Catenin Pathway Small Molecule Inhibitors

    27. Daniel D. Holsworth and Stefan Krauss

    VII. Topics in Drug Design and Discovery

    Section Editor: Peter R. Bernstein, PhaRmaB LLC, Rose Valley, Pennsylvania

  27. Targeted Covalent Enzyme Inhibitors

    28. Mark C. Noe and Adam M. Gilbert

  28. Drug Design Strategies for GPCR Allosteric Modulators

    29. P. Jeffrey Conn, Scott D. Kuduk and Darío Doller

  29. Progress in the Development of Non-ATP Competitive Protein Kinase Inhibitors for Oncology

    30. Campbell McInnes

    VIII. Trends

    Section Editor: Joanne Bronson, Bristol-Myers Squibb, Wallingford, Connecticut

  30. New Chemical Entities Entering Phase III Trials in 2011

    31. Gregory T. Notte

  31. To Market, To Market – 2011Joanne Bronson, Murali Dhar, William Ewing and Nils Lonberg

Subject Areas: Pharmaceutical technology [TDCW], Organic chemistry [PNN], Pharmacology [MMG], Yearbooks, annuals, almanacs [GBCY]
View full details